ArticleRisk management and healthcare policy2020
Risk Assessment of Recurrence and Autoimmune Disorders in Kikuchi Disease.
Article in Risk management and healthcare policy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Diagnostic Challenges and Scientific Management of Suspected Recurrent Kikuchi-Fujimoto Disease: A Case Report.The American journal of case reports · 2026Article
- Kikuchi-Fujimoto disease initially presenting with severe digestive symptoms and progressing to systemic lupus erythematosus: a case report and literature review.Frontiers in pediatrics · 2026Article
- Kikuchi-Fujimoto disease misdiagnosed as tubercular lymphadenitis: A puzzle in cervical lymph nodes.Journal of family medicine and primary care · 2025Article
- Human papilloma virus vaccine induced Kikuchi-Fujimoto disease: A case report.Lung India : official organ of Indian Chest Society · 2025Article
- Recurrence of Histiocytic Necrotizing Lymphadenitis in Children: A 10-year Multicenter Retrospective Study.Journal of inflammation research · 2025Article
- Clinical features and recurrence predictors of histiocytic necrotizing lymphadenitis in Chinese children.Pediatric rheumatology online journal · 2024Article
- Kikuchi-Fujimoto disease: A comprehensive review.World journal of clinical cases · 2023Review
- Macrophage activation syndrome in children with Kikuchi-Fujimoto disease.Pediatric rheumatology online journal · 2023Article
- Case of recurring Kikuchi disease and autoimmune hepatitis.Clinical case reports · 2022Article
- Differential Diagnosis of Histiocytic Necrotizing Lymphadenitis and Malignant Lymphoma with Simple Clinical Findings.Children (Basel, Switzerland) · 2022Article
- Self-limiting COVID-19-associated Kikuchi-Fujimoto disease with heart involvement: case-based review.Rheumatology international · 2022Review
- Comparison of Clinical Characteristics and Risk Factors for Recurrence of Kikuchi-Fujimoto Disease Between Children and Adult.Journal of inflammation research · 2022Article
- Case Report: Two Cases of Kikuchi Disease in West Texas With Non-Self-Limited Disease.Journal of investigative medicine high impact case reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeKikuchi disease (KD) is typically a benign disease. Recent studies reporting recurrence or serious cases suggest a possible association of KD with systemic autoimmune disorders. We performed a long-term analysis of the characteristics of KD in patients of all ages and assessed KD recurrence or progress to systemic autoimmune disorders. PATIENTS AND
methodsElectronic medical records of patients diagnosed with KD between April 1995 and May 2017 were reviewed for clinical and laboratory manifestations.
resultsIn total, 480 patients were confirmed to have KD based on histopathology findings. The mean age at KD diagnosis was 24.4 years. Recurrence occurred in 11.3% of patients; 2.7% developed autoimmune diseases after KD diagnosis. Patients who experienced recurrence had more extranodal symptoms, lymphopenia, and a longer lymphopenia-recovery duration. Patients who developed autoimmune diseases after KD were more likely to have extranodal symptoms, KD recurrence, and anti-nuclear antibody positivity.
conclusionKD patients with risk factors need to be followed-up for KD recurrence and the development of systemic autoimmune diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.